DeepMed Research

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

Phase 2

Terminated

Conditions: IgG4 Related Disease
IgG4-RD

Interventions: Drug: placebo for elotuzumab
Drug: elotuzumab
Drug: methylprednisolone
Drug: diphenhydramine
Drug: acetaminophen
Drug: famotidine
Drug: prednisone

First Posted Date: 2021-06-08

Last Posted Date: 2025-02-25

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 8

Registration Number: NCT04918147

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Mayo Clinic: Pulmonary and Critical Care Medicine, Rochester, Minnesota, United States
🇺🇸
Emory Healthcare, Atlanta, Georgia, United States

Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.

Phase 1

Active, not recruiting

Conditions: HIV Infections

Interventions: Biological: CH505 TF chTrimer
Biological: 3M-05-AF
Biological: Aluminum hydroxide suspension

First Posted Date: 2021-06-07

Last Posted Date: 2024-10-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 52

Registration Number: NCT04915768

Locations: 🇺🇸
Vanderbilt Vaccine (VV) CRS, Nashville, Tennessee, United States
🇺🇸
The Hope Clinic of the Emory Vaccine Center CRS, Decatur, Georgia, United States
🇺🇸
Brigham and Women's CRS, Boston, Massachusetts, United States

Selective CD28 Blockade in Renal Transplant Recipients

Phase 2

Withdrawn

Conditions: Kidney Transplantation
Renal Transplant Recipients

Interventions: Biological: Lulizumab
Drug: Tacrolimus
Biological: Thymoglobulin®
Drug: Methylprednisolone
Drug: Mycophenolate Mofetil
Drug: Prednisone

First Posted Date: 2021-05-26

Last Posted Date: 2023-03-22

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT04903054

Locations: 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States

First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults

Phase 1

Completed

Conditions: Influenza
Seasonal Influenza

Interventions: Biological: Flucelvax
Drug: VRC-GENADJ0110-AP-NV (Adjuplex)
Drug: VRC-FLUMOS0111-00-VP (FluMos-v1)

First Posted Date: 2021-05-21

Last Posted Date: 2025-04-27

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 63

Registration Number: NCT04896086

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines

Phase 1

Completed

Conditions: COVID-19

Interventions: Biological: mRNA-1273
Biological: mRNA-1273.211
Biological: SARS-CoV-2 rS/M1
Biological: BNT162b2
Biological: Ad26.COV2.S
Biological: mRNA-1273.222

First Posted Date: 2021-05-17

Last Posted Date: 2025-04-20

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 867

Registration Number: NCT04889209

Locations: 🇺🇸
University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States
🇺🇸
Cincinnati Children's Hospital Medical Center Vaccine Research Center, Cincinnati, Ohio, United States
🇺🇸
University of Pittsburgh - Medicine - Infectious Diseases, Pittsburgh, Pennsylvania, United States

and more 7 locations

Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)

Phase 1

Completed

Conditions: Gonococcal Infection

Interventions: Drug: Azithromycin
Drug: Ceftriaxone
Drug: Ciprofloxacin
Biological: Neisseria gonorrhoeae strain FA1090 A26
Biological: Neisseria gonorrhoeae strain FA7527

First Posted Date: 2021-05-03

Last Posted Date: 2021-12-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 16

Registration Number: NCT04870138

Locations: 🇺🇸
University of North Carolina Health Care - Infectious Diseases, Chapel Hill, North Carolina, United States

Metabolic Profiling of Immune Responses in Immune-mediated Diseases

Recruiting

Conditions: Atopic Dermatitis
Immune-mediated Diseases
Primary Immunodeficiency
Psoriasis

First Posted Date: 2021-04-29

Last Posted Date: 2025-03-30

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 200

Registration Number: NCT04864886

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations

Completed

Conditions: Immunodeficiencies
Immune Dysregulations

First Posted Date: 2021-04-21

Last Posted Date: 2024-10-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 308

Registration Number: NCT04852276

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19

Phase 3

Completed

Conditions: Covid19

Interventions: Drug: Remdesivir Placebo
Biological: Remdesivir
Drug: Aviptadil Placebo
Biological: Aviptadil
Drug: Corticosteroid

First Posted Date: 2021-04-14

Last Posted Date: 2023-05-03

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 473

Registration Number: NCT04843761

Locations: 🇺🇸
VA Loma Linda Healthcare System (Site 074-017), 11201 Benton Street, Loma Linda, California, United States
🇺🇸
Ronald Reagan UCLA Medical Center (Site 203-002), 757 Westwood Plaza, Los Angeles, California, United States
🇺🇸
Cleveland Clinic Fairview Hosptial (Site 207-005), 18101 Lorain Ave., Cleveland, Ohio, United States

and more 37 locations

A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.

Phase 2

Terminated

Conditions: HIV Infections
CMV
Cytomegalovirus

Interventions: Drug: Letermovir Oral Tablet

First Posted Date: 2021-04-09

Last Posted Date: 2025-03-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 44

Registration Number: NCT04840199

Locations: 🇺🇸
University of Washington Positive Research CRS, Seattle, Washington, United States
🇺🇸
UCSD Antiviral Research Center CRS (Site 701), San Diego, California, United States
🇺🇸
UCSF HIV/AIDS CRS (Site 801), San Francisco, California, United States

and more 12 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy